drugset / Trial / NCT03471559

Cannabidiol - an in Vivo Innovative Drug Delivery Study

NCT03471559

Phase 1 Terminated 8 enrolled Central Institute of Mental Health, Mannheim
RandomizedCrossoverOpen-labelBasic science

Summary

Basic characterization of the drug delivery system for cannabidiol. A comparative bioavailability study.

Timeline

Start
2018-12-10
Primary completion
2019-06-30
Completion
2019-08-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 200 mg Intranasal

Indications

No indication recorded.